Research programme: next-generation biologics - Ambrx/Sino Biopharmaceutical
Latest Information Update: 13 Mar 2024
At a glance
- Originator Ambrx
- Class Antineoplastics; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 28 Feb 2024 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)